Meiji Seika Pharma will present 10 studies on Nacubactam at ESCMID Global 2026 including Phase III Integral-2 results in ...

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs) that will now launch later this year, but turned down a rival product ...

Carbapenem-resistant Enterobacterales (CRE) have been identified by the World Health Organization as critical-priority pathogens, posing a severe global public health threat due to limited therapeutic ...

The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will appeal the decision. Apellis’ ...